A5033878416- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Epigenetics and DNA Methylation
- Blood groups and transfusion
- Helicobacter pylori-related gastroenterology studies
- Multiple Myeloma Research and Treatments
- MicroRNA in disease regulation
- COVID-19 and healthcare impacts
- BRCA gene mutations in cancer
- CAR-T cell therapy research
- Cancer-related gene regulation
- Parathyroid Disorders and Treatments
- Cancer-related Molecular Pathways
- Hemoglobinopathies and Related Disorders
- Reproductive System and Pregnancy
- Cutaneous lymphoproliferative disorders research
- HIV/AIDS drug development and treatment
- T-cell and Retrovirus Studies
- Occupational and environmental lung diseases
- Family Support in Illness
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Myeloid Leukemia Treatments
Columbia University Irving Medical Center
2022-2024
Columbia University
2015-2023
Cancer Genetics (United States)
2022
NewYork–Presbyterian Hospital
2015
To promote the identification of women carrying BRCA1/2 variants, US Preventive Services Task Force recommends that primary care clinicians screen asymptomatic for an increased risk a variant risk.To examine effects patient and clinician decision support about genetic testing compared with standard education alone.This clustered randomized clinical trial was conducted at academic medical center including 67 (unit randomization) 187 patients. Patient eligibility criteria included aged 21 to...
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor cells into fresh, effector-like cells. Antitumor immunity catalyzed by is characterized mobilization in systemic circulation tumor. To address whether abundance blood associated immunotherapy response, we used flow cytometry...
The absence of IFN-γ receptor (IFN-γR) or STAT1 signaling in donor cells has been shown to result reduced induction acute graft-versus-host disease (GVHD). In this study, we unexpectedly observed increased activation and expansion lymphocytes both lymphohematopoietic organs GVHD target tissues IFN-γR/STAT1-deficient recipient mice, leading rapid mortality following the GVHD. LPS-matured, BM-derived Ifngr1-/- Stat1-/- DCs (BMDCs) were more potent allogeneic stimulators expressed levels MHC II...
This secondary analysis of a randomized clinical trial reports primary care clinician outcomes decision support tools for referral patients with potential BRCA1/2 mutations genetic counseling.
Abstract Importance: Given concerns that cancer patients may be at increased risk of COVID-19 and have more severe complications if infected, there been profound changes to routine care. We aimed identify factors for developing among patients. Methods: conducted a retrospective cohort study tested SARS-CoV-2 infection between March 1, 2020 June 6, NewYork-Presbyterian Hospital (NYPH)/Columbia University Irving Medical Center (CUIMC) in New York City. During this time period, all hospitalized...
Abstract Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease. Immune checkpoint inhibitors have thus far failed to improve outcomes due an immunosuppressive tumor microenvironment (TME). In preclinical mouse models, signaling through the C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C ligand 12 (CXCL12) axis results in exclusion of anti-tumor immune cells. Using KPC PDAC model, we demonstrated that treatment with combination CXCR4 inhibitor (CXCR4i),...
Expression of the Notch family receptors is often upregulated in pancreatic ductal adenocarcinoma (PDAC). In this study, we focused on Notch4, which had not been investigated PDAC. We generated KC (
<div>Abstract<p>Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor cells into fresh, effector-like cells. Antitumor immunity catalyzed by is characterized mobilization in systemic circulation tumor. To address whether abundance blood associated immunotherapy...
<div><p>Expression of the Notch family receptors is often upregulated in pancreatic ductal adenocarcinoma (PDAC). In this study, we focused on Notch4, which had not been investigated PDAC.</p><p>We generated KC (<i>LSL-Kras<sup>G12D</sup>;p48-Cre</i>), N4<i><sup>−</sup><sup>/</sup><sup>−</sup></i>KC...
<p>Supplementary Figure 1. Inactivation of Notch1 had no impact on pancreatic tumorigenesis driven by oncogenic Kras in the context p16 inactivation.</p><p>Supplementary 2. Histological analyses tissues PKC, N1+/- and N1fl/flPKC mice revealed significant differences.</p><p>Supplementary 3. Representative H&E from at 2 months age (PanIN, A, C, E) 5 (PDAC, B, D, F).</p><p>Supplementary 4. Comparative histological PanIN lesions 5. Notch4 reduced...
<div>Abstract<p>Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor cells into fresh, effector-like cells. Antitumor immunity catalyzed by is characterized mobilization in systemic circulation tumor. To address whether abundance blood associated immunotherapy...
<div><p>Expression of the Notch family receptors is often upregulated in pancreatic ductal adenocarcinoma (PDAC). In this study, we focused on Notch4, which had not been investigated PDAC.</p><p>We generated KC (<i>LSL-Kras<sup>G12D</sup>;p48-Cre</i>), N4<i><sup>−</sup><sup>/</sup><sup>−</sup></i>KC...
<p>Supplementary Figs. S1-S5</p>
<p>Supplementary Figs. S1-S5</p>
<p>Supplementary Figure 1. Inactivation of Notch1 had no impact on pancreatic tumorigenesis driven by oncogenic Kras in the context p16 inactivation.</p><p>Supplementary 2. Histological analyses tissues PKC, N1+/- and N1fl/flPKC mice revealed significant differences.</p><p>Supplementary 3. Representative H&E from at 2 months age (PanIN, A, C, E) 5 (PDAC, B, D, F).</p><p>Supplementary 4. Comparative histological PanIN lesions 5. Notch4 reduced...